ioCells: Revolutionising Drug Development for Alzheimer’s & Parkinson’s Disease
Time: 11:30 am
day: Discovery Track Day 2 AM
Details:
- Highlighting precision reprogrammed hiPSC-derived microglia from both male and female background expressing key markers (CD45, TREM2), demonstrating phagocytosis, exhibiting cytokine response (LPS,INFɣ) and being ready to be co-cultured with excitatory neurons
- Introducing a toolbox of disease model microglia, glutamatergic neurons and GABAergic neurons carrying disease relevant mutations (e.g., TREM2 R47H, APP V717I) to develop phenotypic screening and functional assays in a multicellular environment with the goal of providing physiologically relevant data to improve translation into the clinic
- Showcasing CRISPR-Ready ioMicroglia and ioGlutamatergic Neurons, offering scalable and consistent CRISPR screens for drug target discovery and validation in human cell types
